Cargando…
A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system
First identified as the etiological agent behind Acquired Immunodeficiency Syndrome (AIDS) in the early 1980s, HIV-1 has continued to spread into a global pandemic and major public health concern. Despite the success of antiretroviral therapy at reducing HIV-1 viremia and preventing the dramatic CD4...
Autores principales: | Pankrac, Joshua, Klein, Katja, McKay, Paul F., King, Deborah F. L., Bain, Katie, Knapp, Jason, Biru, Tsigereda, Wijewardhana, Chanuka N., Pawa, Rahul, Canaday, David H., Gao, Yong, Fidler, Sarah, Shattock, Robin J., Arts, Eric J., Mann, Jamie F. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775397/ https://www.ncbi.nlm.nih.gov/pubmed/29367885 http://dx.doi.org/10.1038/s41541-017-0040-6 |
Ejemplares similares
-
A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection
por: Mann, Jamie F.S., et al.
Publicado: (2020) -
Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1
por: Gao, Yong, et al.
Publicado: (2018) -
Blocking T‐cell egress with FTY720 extends DNA vaccine expression but reduces immunogenicity
por: Mann, Jamie F. S., et al.
Publicado: (2021) -
Eradication of HIV-1 latent reservoirs through therapeutic vaccination
por: Pankrac, Joshua, et al.
Publicado: (2017) -
Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection()
por: Mann, Jamie F.S., et al.
Publicado: (2013)